Journal article
Comparative Trial of HPV-77, DE-5 and RA 27/3 Live-Attenuated Rubella Vaccines
American journal of diseases of children (1960), Vol.124(4), pp.536-538
10/01/1972
DOI: 10.1001/archpedi.1972.02110160074007
PMID: 4562789
Abstract
An experimental live, attenuated rubella vaccine, RA 27/3, was compared with HPV-77, DE-5 rubella vaccine (Meruvax) in children in an open school setting. Seroconversion of RA 27/3 vaccines administered by either intranasal or subcutaneous route and HPV-77, DE-5 given subcutaneously was 95% or greater as measured by hemagglutination-inhibition antibody (HI). However, RA 27/3 vaccine produced significantly greater seroconversion rates and titer levels by complement-fixation antibody (CF) testing, when compared with HPV-77, DE-5 vaccine. No serious reactions were noted, and there were no joint reactions in any study group during the 28-day postimmunization follow-up period or upon recontacting vaccine recipients one year later. Intranasal immunization was well tolerated.
Details
- Title: Subtitle
- Comparative Trial of HPV-77, DE-5 and RA 27/3 Live-Attenuated Rubella Vaccines
- Creators
- Robert B WallacePeter Isacson
- Resource Type
- Journal article
- Publication Details
- American journal of diseases of children (1960), Vol.124(4), pp.536-538
- DOI
- 10.1001/archpedi.1972.02110160074007
- PMID
- 4562789
- NLM abbreviation
- Am J Dis Child
- ISSN
- 0002-922X
- eISSN
- 2374-3018
- Publisher
- American Medical Association
- Language
- English
- Date published
- 10/01/1972
- Academic Unit
- Epidemiology; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984364435302771
Metrics
10 Record Views